This patent application pertains to macrocyclic peptides and their radiolabeled derivatives, generally represented by Formula I. These compounds exhibit selective binding to Granzyme B (GzmB) and hold the potential for imaging disease or disorders associated with elevated GzmB levels. Such conditions include cancer immunotherapy, autoimmunity, wound healing, and inflammation.